DGX · Quest Diagnostics Inc
$238.50
+2.66 (+1.13%)
At close · Aug 6
Market Cap
$26.32B
Shares
110.37M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Remaining Authorization
$1,300,000,000
as of 2026-06-30
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2026-06-30 YTD | $102,000,000 | 10-Q, filed 2026-07-23 |
| 2025-12-31 | $450,000,000 | 10-K, filed 2026-02-26 |
| 2024-12-31 | $151,000,000 | 10-K, filed 2026-02-26 |
| 2023-12-31 | $275,000,000 | 10-K, filed 2026-02-26 |
| 2022-12-31 | $1,408,000,000 | 10-K, filed 2025-02-20 |
| 2021-12-31 | $2,199,000,000 | 10-K, filed 2024-02-22 |
| 2020-12-31 | $325,000,000 | 10-K, filed 2023-02-21 |
| 2019-12-31 | $353,000,000 | 10-K, filed 2022-02-28 |
| 2018-12-31 | $322,000,000 | 10-K, filed 2021-02-22 |
| 2017-12-31 | $465,000,000 | 10-K, filed 2020-02-20 |
| 2016-12-31 | $590,000,000 | 10-K, filed 2019-02-21 |
| 2015-12-31 | $224,000,000 | 10-K, filed 2018-02-23 |
| 2014-12-31 | $132,000,000 | 10-K, filed 2017-02-22 |
| 2013-12-31 | $1,037,000,000 | 10-K, filed 2016-02-26 |
| 2012-12-31 | $200,000,000 | 10-K, filed 2015-02-24 |
| 2011-12-31 | $935,000,000 | 10-K, filed 2014-02-18 |
| 2010-12-31 | $750,000,000 | 10-K, filed 2013-02-27 |
| 2009-12-31 | $499,991,000 | 10-K, filed 2012-02-16 |
| 2008-12-31 | $253,997,000 | 10-K, filed 2011-02-16 |
| 2007-12-31 | $145,660,000 | 10-K, filed 2010-02-17 |
Key facts
CIK
1022079
CUSIP
74834L100
13F (30d)
578 filings
551 filers
Visit website
Investor relations